In a recent report, Santiment projected that the price of AVAX will soon surpass Solana’s gains, despite enthusiasm surrounding Solana’s potential ETF approval. Today saw an over 7% rally in both AVAX and SOL, provoking increased market optimism and renewed interest from investors. Notable on-chain data suggests the potential for continued price increases for both